Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure

Circulation

Volumn 103, Issue 7, 2001, Pages 973-980

  Torre Amione, Guillermo ^a,b   Young, James B ^c   Durand, Jean Bernard ^a   Bozkurt, Bykem ^a   Mann, Douglas L ^a   Kobrin, Isaac ^d   Pratt, Craig M ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ACTELION PHARMACEUTICALS LTD   (Switzerland)

Author keywords

Endothelin; Heart failure; Hemodynamics

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; PLACEBO; TEZOSENTAN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART INDEX; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MUSCLE CRAMP; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; THORAX PAIN; TREATMENT OUTCOME; VASODILATATION;

EID: 0035916270     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.7.973     Document Type: Article

References (34)

1. Heart Failure Society of America (HFSA) practice guidelines: HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches
2. Heart failure: Evaluation and treatment of patients with left ventricular systolic dysfunction: Agency for Health Care Policy and Research (AHCPR)
3. Inotropic therapy for heart failure
4. Newer drug therapy for congestive heart failure
5. Increased endothelin in experimental heart failure
6. Role of endothelin in the exercise intolerance of chronic heart failure
7. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure
8. Molecular characterization of endothelin receptors
9. Endothelin-1 modulates vascular smooth muscle structure and vasomotion: Implications in cardiovascular pathology
10. Presence of non-selective type of endothelin receptor on vascular endothelium and its linkage to vasodilation
11. Expression of endothelin-1, ETA and ETB receptors, and ECE and distribution of endothelin-1 in failing rat heart
12. Coordinated upregulation of the cardiac endothelin system in a rat model of heart failure
13. Endothelin B receptors in rabbit pulmonary resistance arteries: Effect of left ventricular dysfunction
14. Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure
15. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure
16. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure
17. A receptor blockade in patients with congestive heart failure
18. Pharmacology of tezosentan, new endothelin receptor antagonist designed for parenteral use
19. Both ETA and ETB receptors mediate contraction to endothelin-1 in human blood vessels
20. Pathophysiology of endothelin in the cardiovascular system
21. Endogenous endothelin-1 depresses left ventricular systolic and diastolic performance in congestive heart failure
22. Contrasting inotropic effects of endogenous endothelin in the normal and failing human heart: Studies with an intracoronary ET(A) receptor antagonist
23. Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors
24. Endothelin system-dependent cardiac remodeling in renovascular hypertension
25. Different contributions of endothelin-A and endothelin-B receptors in the pathogenesis of deoxycorticosterone acetate-salt-induced hypertension in rats
26. ET-receptor antagonism, myocardial gene expression, and ventricular remodeling during CHF in rats
27. The cardiac endothelin system in established pressure overload left ventricular hypertrophy
28. Cardiac growth factors in human hypertrophy: Relations with myocardial contractility and wall stress
29. Effects of physiological or pathological pressure load in vivo on myocardial expression of ET-1 and receptors
30. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes: A paracrine mechanism for myocardial cell hypertrophy
31. Effects of endothelins on collagen turnover in cardiac fibroblasts
32. Factors causing arrhythmias in chronic congestive heart failure
33. Hypotension with dobutamine: Beta-adrenergic antagonist selectivity at low doses of carvedilol
34. Incidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failure